{"nctId":"NCT00912925","briefTitle":"Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I","startDateStruct":{"date":"2000-12"},"conditions":["Mucopolysaccharidosis I","Hurlers Syndrome","Hurler-Scheie Syndrome"],"count":45,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"Aldurazyme treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rhIDU (recombinant human-Alpha-L-Iduronidase)"]}],"interventions":[{"name":"rhIDU (recombinant human-Alpha-L-Iduronidase)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient had a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and a fibroblast or leukocyte alpha-L-iduronidase enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory.\n* Female patients of childbearing potential had a negative pregnancy test (urine-beta-human chorionic gonadotropin (hCG)) at baseline (all female patients of childbearing potential and sexually mature male patients were advised to use a medically accepted method of contraception throughout the study).\n* The patient was capable of standing independently for 6 minutes and walking a minimum of 5 meters within 6 minutes.\n* The patient was capable of performing a reproducible FVC maneuver.\n* The patient had a baseline FVC value that was less than or equal to 80% of the patient's predicted normal FVC value based on polgar predicted values for standing height for children 5 through 7 years of age and the Hankinson predicted values for ages 8 and above.\n\nExclusion Criteria:\n\n* The patient had undergone a tracheostomy.\n* The patient had previously undergone a bone marrow transplantation.\n* The patient was pregnant or lactating.\n* The patient has received an investigational drug within 30 days prior to study enrollment.\n* The patient had a medical condition, serious intercurrent illness, or other extenuating circumstance that could have significantly interfered with study compliance including all prescribing evaluations and follow-up activities.\n* The patient had a known hypersensitivity to rhIDU or to components of the active or placebo test solutions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC)","description":"Percent Predicted Forced Vital Capacity (FVC): the maximal exhaled breathe volume following a maximal inhaled breath. Overall Change from Baseline to Week 26 in percent predicted FVC = (observed value)/(predicted value) \\* 100%). A higher value indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":"16.00"},{"groupId":"OG001","value":"48.4","spread":"14.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":"13.13"},{"groupId":"OG001","value":"50.2","spread":"17.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"7.12"},{"groupId":"OG001","value":"1.8","spread":"7.70"}]}]}]},{"type":"PRIMARY","title":"Overall Change From Baseline to Week 26 in Six Minute Walk Test (6MWT)","description":"Six Minute Walk Test (6MWT): Distance walked (measured in meters) in 6 minutes. A longer distance indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"366.7","spread":"113.68"},{"groupId":"OG001","value":"319.1","spread":"131.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"348.3","spread":"128.82"},{"groupId":"OG001","value":"338.8","spread":"127.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.4","spread":"67.49"},{"groupId":"OG001","value":"19.7","spread":"68.56"}]}]}]},{"type":"SECONDARY","title":"Overall Change From Baseline to Week 26 in Apnea/Hypopnea Index (AHI)","description":"Apnea/Hypopnea Index (AHI): Number of absent (apnea) and shallow (hypopnea) breaths per hour of sleep. Overall change from Baseline to Week 26 in AHI. A greater decrease in events indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"15.20"},{"groupId":"OG001","value":"20.5","spread":"19.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":"14.93"},{"groupId":"OG001","value":"17.6","spread":"16.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"8.55"},{"groupId":"OG001","value":"-2.9","spread":"6.66"}]}]}]},{"type":"SECONDARY","title":"Overall Percent Change From Baseline to Week 26 in Liver Volume","description":"Liver Organ Volume: Volume of liver measured by Magnetic Resonance Imaging (MRI). Greater decrease in volume indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1368.1","spread":"314.88"},{"groupId":"OG001","value":"12212.2","spread":"283.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1366.5","spread":"316.94"},{"groupId":"OG001","value":"979.8","spread":"321.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"19.22"},{"groupId":"OG001","value":"-18.9","spread":"19.44"}]}]}]},{"type":"SECONDARY","title":"Overall Change From Baseline to Week 26 in Child Health Assessment Questionnaire/Health Assessment Questionnaire (CHAQ/HAQ) Disability Index Score","description":"CHAQ/HAQ) = Patient questionnaire that measures the degree of disability on a scale of 0 (no disability) to 3 (maximal disability). A lower score indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.60"},{"groupId":"OG001","value":"2.0","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.71"},{"groupId":"OG001","value":"1.9","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.43"},{"groupId":"OG001","value":"-0.2","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Overall Change From Baseline to Week 26 in Active Joint Range of Motion (ROM)","description":"Active Joint Range of Motion (ROM): Shoulder Flexion Ability to maximally raise one's arm overhead without assistance. Shoulder range of motion (mean of left and right arms) measured in degrees (0-180) by goniometry. Greater degree of flexion indicates greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":"23.99"},{"groupId":"OG001","value":"96.1","spread":"30.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":"32.66"},{"groupId":"OG001","value":"88.9","spread":"37.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"27.18"},{"groupId":"OG001","value":"-1.2","spread":"29.78"}]}]}]},{"type":"SECONDARY","title":"Overall Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) Levels","description":"Urinary Glycosaminoglycan (GAG) Levels: Concentration of GAG relative to creatinine in urine. A greater decrease in GAG level indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183.3","spread":"72.05"},{"groupId":"OG001","value":"188.9","spread":"60.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250.2","spread":"105.09"},{"groupId":"OG001","value":"81.3","spread":"26.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":"59.34"},{"groupId":"OG001","value":"-54.1","spread":"19.49"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Headache","Pyrexia","Diarrhoea","Vomiting","Rash"]}}}